Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Prevacid NapraPAC Scripts Suggest PPI/NSAID Combos May Thrive Post-Vioxx

This article was originally published in The Tan Sheet

Executive Summary

TAP's Prevacid NapraPAC is among the early winners in the arthritis market following the withdrawal of Merck's Vioxx, IMS Health data suggest
Advertisement

Related Content

TAP Licenses Prevacid To Novartis For 2009 Switch
TAP Licenses Prevacid To Novartis For 2009 Switch
TAP Licenses Prevacid To Novartis For 2009 Switch
PPI Marketers Target Patients Leaving COX-2s For NSAIDs
PPI Marketers Target Patients Leaving COX-2s For NSAIDs
PPI Marketers Target Patients Leaving COX-2s For NSAIDs
Aspirin Plus PPI Less Likely Than Clopidogrel To Cause GI Events – Study
Aspirin Plus PPI Less Likely Than Clopidogrel To Cause GI Events – Study
Aspirin Plus PPI Less Likely Than Clopidogrel To Cause GI Events – Study

Topics

Advertisement
UsernamePublicRestriction

Register

PS097627

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel